CRDL (Cardiol) Bathi resik saben saham (EPS TTM)

Logo perusahaan publik Cardiol (CRDL)

Current partnerships with medical centers combating cardiac inflammation establish a short-term foundation, yet long-term growth is driven by FDA orphan statuses and the final testing stages of Cardiol Therapeutics (CRDL). The rolling year earnings per share (EPS) illustrates this balance, with the metric currently standing at -0.24. An innovative cannabidiol-based pipeline and high R&D efficiency confirm the asset's development potential.

CRDL Bathi resik saben siji saham sajrone rolas wulan pungkasan Cardiol Therapeutics (04.07.2022 - 16.11.2026)

Rincian analitis perusahaan cardiolrx.com (CRDL)

Ringkesan analitik perusahaan:Cardiol (CRDL)
Barang unggulan Cardiol Therapeutics

The metric is calculated by dividing the total annual net income by the number of shares outstanding. This metric smooths out quarterly lags, separating the fundamental trend from market noise. For Cardiol Therapeutics (CRDL), which invests in R&D for anti-inflammatory therapy, EPS reflects the cost of developing new formulas. Analyzing the 12-month EPS trend on GURU.Markets allows for an assessment of the efficiency of innovation spending. This chart's price action determines the company's investment attractiveness relative to its competitors.